1 Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D´Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, and Gatell JM for the BEST study team.
AIDS. 2003,17:831-840.abstract

2 An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Writing Committee: Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG, for the HIV Lipodystrophy Case Definition Study Group.
Lancet. 2003;361(9359):726-35. abstract

3 S-adenosylmethionine in plasma to test for Pneumoscystis carinii pneumonia.
Helweg-Larsen J.
Lancet. 2003 ;361(9365):1237. abstract

4 Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, Colebunders R, Chiesi A, Lundgren JD, Phillips AN for the EuroSIDA group.
J Acquir Immune Defic Syndr 2003 ;32(4):452-61 abstract

5 Modelling the three year risk of myocardial infarction among participants in the D:A:D study. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD, for the DAD Study Group.
HIV Med. 2003; 4(1):1-10. abstract

6 Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, for the DAD study group
AIDS. 2003; 17(8):1179-1193 abstract

7 Changes in viral load in people with virological failure who remain o­n the Same HAART regimen. Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgren JD.
Antivir Ther. 2003 ;8(2):127-36 abstract

8 Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD, for the EuroSIDA study group.
Lancet. 2003; 362: 22–29. abstract

9 Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A; The EuroSIDA Study Group.
HIV Med. 2003 Jul;4(3):255-262. abstract

10 K65R with and withourt S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Røge BT, Katzenstein TL, Obel N, Pedersen C, Mathiesen L, Lundgren JD and Gerstoft J.
Antivir Ther. 2003; 8:173-182 abstract

11 Randomised trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in HIV-1 infected patients: The MaxCmin1 Trial. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD for the MaxCmin1 trial group.
J Infect Dis. 2003;188:635-642 abstract

12 Virological rebound after suppression o­n highly active antiretroviral therapy. Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel F-D, Phillips AN, Clotet B, Lundgren JD, for the EuroSIDA study group.
AIDS. 2003 ;17(12):1741-1751 abstract

13 Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Writing Committee: Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME, for the Antiretroviral Therapy Cohort Collaboration.
Lancet. 2003 ;362(9385):679-86 abstract

14 Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The Data Collection o­n Adverse Events of Anti-HIV Drugs for the D:A:D Study Group.
Writing Committee: Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD, for the DAD Study group.
N Engl J Med. 2003; 349(21);1993-2003. abstract

15 Monitoring of long-term toxicities of HIV treatments: an international perspective. Bisson G, Gross R, Miller V, Weller I, Walker A, o­n behalf of the wrinting group: Arlett P, Carr A, Evans S, Graham D, Justice A, Kreft-Jais C, Lundgren JD, Munk B, Murray J, Pirmohamed M, Pizzuti D, Szarfman A.
AIDS. 2003;17:2407-2417 abstract

16 Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugs. Lundgren JD.
Pharmacoepidemiol Drug Saf. 2003; 12:357-359 abstract

17 Anemia and Survival in Human Immunodeficiency Virus. Lundgren JD and Mocroft A.
Clin Infect Dis. 2003;37(Suppl. 4):S297-303 abstract

18 Low efficacy and high frequency of adverse event in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD.
AIDS. 2003; 17(14):2045-2022 abstract

19 A randomized trial comparing initial HAART regimens for nelfinavir/nevirapine and ritonavir/saquinavir in combinatin with two nucleoside reverse transcriptase inhibitors. Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
Antivir Ther. 2003; 8(6):595-602 abstract

Updated: 23 Feb 2006